Try our mobile app

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Published: 2023-02-08 13:00:00 ET
<<<  go to MDGL company page

CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor conferences:

SVB Securities Global Biopharma Conference4:20 pm ET on Tuesday, February 14, 2023.

Cowen Annual Healthcare Conference2:50 pm ET on Monday, March 6, 2023.

Oppenheimer Annual Healthcare Conference 10:40 am ET on Monday, March 13, 2023.

The presentations will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.

About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.

Investor Contact Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media ContactChristopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Primary Logo

Source: Madrigal Pharmaceuticals, Inc.